Description

Rizendros 35 (Risedronic Acid) Coated Tablets 35 mg. №4

Ingredients

Active ingredient: Risedronic acid 35 mg.
Other ingredients: lactose monohydrate, microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, titanium dioxide, macrogol.

Dosage

Recommended dosage: One tablet once a week, taken on the same day each week, preferably in the morning, at least 30 minutes before the first food, beverage, or medication of the day.

Indications

Rizendros 35 tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women to reduce the risk of fractures, including those of the hip and spine.

Contraindications

Do not use Rizendros 35 tablets if:

• You have a hypersensitivity to risedronic acid or any of the tablet’s components.
• You have certain esophageal conditions that delay esophageal emptying.
• You are unable to stand or sit upright for at least 30 minutes.

Directions

It is important to follow the instructions provided by your healthcare provider. Swallow the tablet whole with a full glass of plain water (6 to 8 ounces), and do not lie down for at least 30 minutes after taking the tablet.

Scientific Evidence

Risedronic acid, the active ingredient in Rizendros 35 tablets, belongs to the bisphosphonate class of drugs known for their efficacy in reducing bone resorption and increasing bone mineral density. Clinical trials have demonstrated the effectiveness of risedronic acid in reducing the risk of fractures in postmenopausal women with osteoporosis.

Additional Information

It is essential to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements, before starting Rizendros 35 treatment. Regular monitoring of bone density and calcium levels may be recommended during therapy with risedronic acid.

Pharmacological Effects: Risedronic acid inhibits osteoclast-mediated bone resorption, leading to an increase in bone mineral density and a decrease in the risk of fractures. It acts by binding to hydroxyapatite crystals in bone, interfering with osteoclast activity.

Clinical Trials: A study published in the Journal of Bone and Mineral Research showed that treatment with risedronic acid significantly reduced the incidence of vertebral fractures in postmenopausal women with osteoporosis compared to a placebo group.